高级检索
当前位置: 首页 > 详情页

A polymorphism at the microRNA binding site in the 3 ' untranslated region of RYR3 is associated with outcome in hepatocellular carcinoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Hosp 2, Dept Gastroenterol & Hepatol, Shijiazhuang 050000, Hebei, Peoples R China [2]Hebei Med Univ, Hosp 4, Dept Gastroenterol & Hepatol, Shijiazhuang, Hebei, Peoples R China [3]Hebei Med Univ, Hosp 2, Dept Pharm, Shijiazhuang 050000, Hebei, Peoples R China
出处:
ISSN:

关键词: SNP rs1044129 RYR3 hepatocellular carcinoma outcome

摘要:
Objective: MicroRNAs can bind to the 3' untranslated regions (UTRs) of messenger RNAs, where they interfere with the translation of targeting genes, thereby regulating cell differentiation, apoptosis, and tumorigenesis. In this study, three microRNA binding site single nucleotide polymorphisms (SNPs) located in the 3' UTR of RYR3 (rs1044129), C14orf101 (rs4901706), and KIAA0423 (rs1053667) were genotyped to assess their relationships with the risks and outcomes of hepatocellular carcinoma (HCC). Methods: The SNPs were genotyped with the ligation detection reaction method. Renilla luciferase reporter assays were used to measure the binding affinity between microRNA 367 and RYR3. Survival curves were calculated using the Kaplan-Meier method, and comparisons between the curves were made using the log-rank test. Multivariate survival analysis was performed using a Cox proportional hazards model. Results: It was found that rs1044129 at the 3' UTR of RYR3 was related to postoperative survival in HCC, with the AA type associated with longer survival times as per the log-rank test. After adjusting with the Cox model, rs104419 was identified as an independent predictor of HCC survival (relative risk: 1.812; 95% confidence interval: 1.026-3.201; P=0.041). Luciferase analysis also indicated the different binding affinities between the SNPs of rs1044129 and microRNA 367. Conclusion: The SNP in the microRNA binding site of RYR3 can be used as a valuable biomarker when predicting HCC outcomes.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2015]版:
大类 | 4 区 医学
小类 | 4 区 生物工程与应用微生物 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 生物工程与应用微生物 4 区 肿瘤学
JCR分区:
出版当年[2015]版:
Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q3 ONCOLOGY
最新[2024]版:
Q2 ONCOLOGY Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Hosp 2, Dept Gastroenterol & Hepatol, Shijiazhuang 050000, Hebei, Peoples R China
通讯作者:
通讯机构: [1]Hebei Med Univ, Hosp 2, Dept Gastroenterol & Hepatol, Shijiazhuang 050000, Hebei, Peoples R China [*1]Department of Gastroenterology and Hepatology, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei, People’s Republic of China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号